Autophagy regulation by acetylation—implications for neurodegenerative diseases by Son, Sung Min et al.
Son et al. Experimental & Molecular Medicine (2021) 53:30–41
https://doi.org/10.1038/s12276-021-00556-4 Experimental & Molecular Medicine
REV I EW ART ICLE Open Ac ce s s
Autophagy regulation by acetylation—implications
for neurodegenerative diseases
Sung Min Son1,2, So Jung Park1,2, Marian Fernandez-Estevez1,2 and David C. Rubinsztein 1,2
Abstract
Posttranslational modifications of proteins, such as acetylation, are essential for the regulation of diverse physiological
processes, including metabolism, development and aging. Autophagy is an evolutionarily conserved catabolic process
that involves the highly regulated sequestration of intracytoplasmic contents in double-membrane vesicles called
autophagosomes, which are subsequently degraded after fusing with lysosomes. The roles and mechanisms of
acetylation in autophagy control have emerged only in the last few years. In this review, we describe key molecular
mechanisms by which previously identified acetyltransferases and deacetylases regulate autophagy. We highlight how
p300 acetyltransferase controls mTORC1 activity to regulate autophagy under starvation and refeeding conditions in
many cell types. Finally, we discuss how altered acetylation may impact various neurodegenerative diseases in which
many of the causative proteins are autophagy substrates. These studies highlight some of the complexities that may
need to be considered by anyone aiming to perturb acetylation under these conditions.
Introduction
Macroautophagy (hereafter autophagy) is a process
mediating the delivery of cytoplasmic components to the
lysosome for degradation via double-membrane vesicles
called autophagosomes1. In mammalian cells, autopha-
gosomes are formed from cup-shaped precursor struc-
tures called phagophores, which include a complex of
autophagy proteins, including ATG5, ATG12 and
ATG16L12. The membranes of phagophores expand and
form enclosed autophagosomes, and completed autop-
hagosomes subsequently fuse with lysosomes2,3. Lysoso-
mal digestion of autophagic cargoes protects cells against
starvation and related stresses by releasing recycled
building blocks from autophagic substrates.
Acetylation is a major posttranslational modification
(PTM) and affects diverse aspects of protein function by
altering properties such as stability, hydrophobicity,
enzymatic activity, subcellular localization and interac-
tions with other substrates and cofactors in the cell4. In
acetylation, the acetyl group of an acetyl-coenzyme (Ac-
CoA) can be co- or posttranslationally transferred to
either the α-amino group of the N-terminus of a protein
(Nt-acetylation) or to the ε-amino group of a lysine resi-
due (K-acetylation). Nt-acetylation is catalyzed by highly
conserved Nt-acetyltransferases (NATs) and is considered
irreversible. On the other hand, K-acetylation is a rever-
sible modification mediated by lysine acetyltransferases
(KATs) at the ε-amino group of lysine residues. The tight
regulation of acetylation by these enzymes plays funda-
mental regulatory roles in development and diverse
human diseases, including diabetes and neurodegenera-
tive conditions4.
In this review, we describe how autophagy is regulated
by acetylation, particularly K-acetylation, by previously
identified KATs and deacetylases (KDACs). We also
summarize the therapeutic targeting of acetylation, which
may potentially lead to effective strategies to treat neu-
rodegenerative diseases.
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Under normal conditions, cells sustain basal levels of
autophagy to maintain homeostasis. However, a variety of
stimuli, including nutrient deprivation, metabolic imbal-
ance or cellular stress, can activate autophagy2,3. Autop-
hagosome biogenesis includes three early stages:
initiation, nucleation, and expansion of the isolation
membrane (Fig. 1), and the process is mediated by
autophagy-related proteins (ATGs)2, which were initially
discovered in yeast5. Many ATG proteins can be regulated
by PTMs, such as phosphorylation, ubiquitination and
acetylation6. The Unc-51-like autophagy-activating kinase
(ULK) 1/2 complex (consisting of ULK1, ATG13, RB1-
inducible coiled-coil protein 1 (FIP200) and ATG101)
plays a major role in autophagy as a signaling node for
several pathways and by phosphorylating downstream
effectors. During the initiation of autophagosome forma-
tion, this complex acts as a serine/threonine kinase that
phosphorylates Beclin 1 in the vacuolar protein-sorting
34/PI3-kinase (VPS34)/PI3K complex7. Additionally, the
ULK1 complex recruits ATG9, which is thought to be
involved in delivering membranes to autophagosomal
structures and may act as a lipid scramblase8–10. The
VPS34/PI3K complex generates phosphatidylinositol 3-
phosphate (PI3P), which facilitates the recruitment of
WD-repeat protein-interacting with phosphoinositides
(WIPI2) that recruits the ATG5-ATG12-ATG16L1
complex to the sites of phagophore formation11. This
complex enables the conjugation of LC3 and its family
members to phosphatidylethanolamine in phagophore
membranes12. To degrade the autophagosomal content,
autophagosomes must fuse with a functional lysosome,
and SNARE proteins mediate this fusion13.
Autophagy is tightly regulated by intracellular and
extracellular signals14. Mechanistic target of rapamycin
(mTOR) complex 1 (mTORC1) integrates signals related
to growth and metabolism in response to nutrient and
energy levels and negatively regulates autophagy15
through the hosphorylation of ULK1, ATG13, transcrip-
tion factor EB (TFEB) and other autophagy-related pro-
teins under nutrient-rich conditions.
Regulation of acetylation in cells
Nt-acetylation
Six different NATs have been identified in mammals
(NatA to NatF)16. NATs regulate the transfer of an acetyl
group from Ac-CoA to the free α-amino group of a poly-
peptide chain that is being synthesized. NATs can differ in
their subunit composition and substrate specificity17. Nt-
acetylation can regulate the subcellular localization of pro-
teins, protein stability, and protein-protein interactions4.
K-acetylation
Lysine (K) acetylation depends on the use of Ac-CoA,
and also nicotine adenine dinucleotide (NAD+) in the
case of sirtuins, a class of lysine deacetylases (KDACs;
HDACs), which use it as a co-substrate. This type of
acetylation links metabolism with cell signaling, as Ac-
CoA and NAD+ are key metabolites18, and modifies
pathways that can be reversibly altered by deacetylases
(Fig. 2). The K-acetylation and deacetylation of proteins
were first studied in histones because of their roles in gene
Fig. 1 Overview of the autophagy pathway. mTORC1 inhibition and AMPK activation positively regulate the ULK1 complex through a series of
phosphorylation events. The ULK1 complex subsequently activates VPS34/PI3K complexes, which leads to PI3P synthesis and the nucleation of
preautophagosomal structures. PI3P then recruits PI3P effector proteins, namely, WIPIs and the ATG12-ATG5-ATG16L1 complex, which is essential for
autophagosome membrane elongation. Subsequent fusion to lysosomes results in the degradation of a variety of substrates, such as protein
aggregates, infectious agents, and damaged mitochondria.
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regulation. However, KATs and KDACs also acetylate
nonhistone proteins in the nucleus or cytoplasm to reg-
ulate major biological processes19. Acetylation also occurs
through nonenzymatic mechanisms and is affected by the
availability of Ac-CoA20,21.
KATs and KDACs and autophagy regulation
To date, approximately 40 mammalian proteins have
been proposed to possess endogenous KAT activity.
Thirteen are well characterized (canonical) and can be
classified into three major families: the GCN5 (also known
as KAT2A) and PCAF (also known as KAT2B) family
(together members of the overarching GNAT family); the
E1A binding protein p300 (encoded by EP300, also known
as KAT3B) and CREB-binding protein (CBP, also known
as KAT3A) family; and the MYST family, named for its
founding members MOZ (also known as KAT6A), yeast
Ybf2, Sas2, and Tip6 (also known as KAT5)22 (Fig. 2). All
canonical KATs are predominantly localized in the
nucleus and acetylate histones and nonhistone proteins.
However, some KATs, such as p300, are nuclear but can
be exported to the cytoplasm depending on intracellular
signaling23. The substrate specificities of KATs are
thought to be defined by their specific subcellular locali-
zation, their interacting proteins and the accessibility of
lysine residues in substrate proteins19. KATs are found in
unique complexes that influence their target specificities
and their abilities to interact with other proteins22. More
than 2,000 acetylation targets in the nucleus, cytoplasm,
mitochondria and endoplasmic reticulum have been
identified in human cells24.
The human genome encodes 18 KDACs, and they are
divided into two major categories: zinc-dependent
KDACs and NAD+ -dependent sirtuin deacetylases
(Table 1). On the basis of phylogenetic conservation and
sequence similarities, zinc-dependent KDACs are further
divided into four classes: class I, class IIa, class IIb and
class IV25. Class I and class IV KDACs are localized in the
nucleus, class IIb KDACs are cytoplasmic, and class IIa
KDACs are primarily localized in the nucleus but are also
found in the cytoplasm. Sirtuin (SIRT) deacetylases
localize to different cellular compartments26, including
the nucleus (SIRT1, SIRT6 and SIRT7), cytoplasm
(SIRT2) and mitochondria (SIRT3, SIRT4 and SIRT5).
In mammalian cells, KATs and KDACs play pivotal
roles in autophagy regulation at multiple steps27 (Table 1).
As protein acetylation is a major regulator of gene tran-
scription, the epigenetic regulation of autophagy genes by
KATs or KDACs may be important for autophagy reg-
ulation. Depending on the target proteins of KATs and
KDACs, acetylation has the potential to induce or inhibit
autophagy (Table 1).
Regulation of autophagy by p300-dependent acetylation
Among KATs, p300 appears to acetylate many ATG
proteins that regulate autophagy at multiple steps27–29
(Table 1). p300 depletion or specific p300 inhibitors can
induce autophagy, whereas the overexpression of p300
inhibits autophagy28,29.
Recently, we reported that under nutrient-depleted
conditions, such as amino acid (AA) or leucine starva-
tion, p300-dependent acetylation regulates autophagy
through the acetylation of the mTORC1 component
Raptor at K109730. This acetylation of Raptor enables the
interaction of mTORC1 with the Rag complex on the
lysosomal membrane, where mTORC1 is activated. In this
way, Raptor acetylation is mediated by leucine, and p300
activation results in mTORC1 activation and autophagy
repression. Cells expressing an acetylation-dead mutant of
Raptor (Raptor K1097R; KR) manifested autophagy acti-
vation without altered acetylation of autophagy-related
proteins. Furthermore, p300 activation had no discernible
effects on autophagy levels in Raptor KR-expressing cells
or in cells where mTORC1 was inhibited. Thus, our data
suggest that p300 activity (and leucine) inhibits autophagy
primarily by activating mTORC1 rather than by altering
the acetylation of other proteins30. This Ac-CoA-p300-
Raptor regulation of autophagy via mTORC1 occurs in
most cell types, including neurons (Fig. 3).
Fig. 2 Regulation of lysine acetylation. a Lysine acetylation is a
reversible posttranslational modification of proteins, including
histones. Proteins can be acetylated at lysine residues (Ac-K) by
specific enzymes, i.e., KATs, or deacetylated by KDACs. b Most
canonical mammalian KATs are classified into three major families: The
p300/CBP, GNAT and MYST family. KDACs are divided into two
categories: classical Zn2+ -dependent HDACs and NAD+ -dependent
sirtuin deacetylases. KDACs can be further grouped into class I, class
IIa, class IIb, class III and class IV.
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The regulation of autophagy by other KATs
1. GNAT familyIn mammalian cells and Drosophila,
GCN5 inhibits the biogenesis of autophagosomes
and lysosomes by regulating the acetylation of TFEB
at lysine 274 and lysine 279. The acetylation of TFEB
disturbs its dimerization and its subsequent binding
to target gene promoters, many of which regulate
autophagy or lysosomal biogenesis31. PCAF, another
member of the GNAT family, is reported to regulate
autophagy through the inhibition of the mTORC1
pathway in some cancers, such as hepatocellular
carcinoma32.
2. MYST familyThe MYST acetyltransferase family
also appears to regulate autophagy. Serum
deprivation leads to the association of the protein
kinase GSK3β with TIP60/KAT5 and subsequent
phosphorylation at serine 86 of TIP60.
Phosphorylated TIP60 acetylates and activates
ULK133, which is essential for serum deprivation-
induced autophagy. Additionally, under nutrient
starvation, the induction of autophagy is coupled
Table 1 KATs and KDACs on regulation of autophagy.
Class Representatives Effect on autophagy Main subcellular location Ref.
KATs p300/CBP family CBP/KAT3A Induction Nucleus 27
Inhibition Nucleus 30
p300/KAT3B Inhibition Nucleus 28–30
GNAT family GCN5/KAT2A Inhibition Nucleus 31
PCAF/KAT2B Induction Nucleus 32
HAT1/KAT1 Not reported Nucleus —
MYST family TIP60/KAT5 Induction Nucleus 33
MOZ/KAT6A Not reported Nucleus —
MORF/KAT6B Not reported Nucleus —
HBO1/KAT7 Not reported Nucleus —
MOF/KAT8 Inhibition Nucleus 34
KDACs Class I HDAC1 No effect Nucleus 37,38
Inhibition 35,36
HDAC2 Induction Nucleus 37
HDAC3 Inhibition Nucleus 27
HDAC8 Inhibition Nucleus 42
Class IIa HDAC4 Inhibition Nucleus 39,40
HDAC5 Inhibition Nucleus 40
HDAC7 Inhibition Nucleus 41
HDAC9 Inhibition Nucleus 43
Class IIb HDAC6 Induction Cytoplasm 44–47
HDAC10 Induction Cytoplasm 48
Class IV HDAC11 Not reported Nucleus —
Class III (Sirtuins) SIRT1 Induction Nucleus 49,50
SIRT2 Inhibition Cytoplasm 51
SIRT3 Induction Mitochondria 52
SIRT4 Induction Mitochondria 55
SIRT5 Induction Mitochondria 53
SIRT6 Induction Nucleus 54
SIRT7 Induction Cytoplasm 56
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to a reduction in histone H4 lysine 16 (H4K16)
acetylation through the downregulation of MOF/
KAT834.
The regulation of autophagy by KDACs
1. KDACs familyKDAC family members are important
for the regulation of autophagy at several levels.
HDAC1 has been reported to be overexpressed in
hepatocellular carcinoma, and inhibition of HDAC1
induces autophagy to repress tumor cell growth35.
Chemical or genetic HDAC1 inhibition also induces
autophagy and lysosomal activity in HeLa cells36.
However, knocking down HDAC2, but not HDAC1,
inhibited autophagy in cardiomyocytes37. In
contrast, the deletion of both HDAC1 and HDAC2
in mice blocked autophagic flux in skeletal muscle38.
Knocking down class IIa HDAC4 leads to autophagy
induction by increasing the expression levels of ATG
proteins, including Beclin 1 and ATG739.
MicroRNA-dependent protein acetylation can also
regulate autophagy. The regulation of HDAC4 and
HDAC5 by miRNA-9 increased total LC3B and
Rab7 levels40. Another study showed that the HDAC
inhibitor suberoylanilide hydroxamic acid (SAHA)
decreased HDAC7 protein levels in endometrial
stromal sarcoma cells, producing an accumulation of
autophagic vacuoles41. Recently, the HDAC8-
selective inhibitor HMC was shown to induce
autophagy in MCF-7 cells42. In response to
hypoxia in a myoblast cell line, class IIa HDAC9
was significantly increased, thereby inhibiting
intracellular autophagy through direct binding to
the promoter regions of Beclin 1, ATG7 and LC343.
Class IIb HDAC6 is the only mammalian deacetylase
that contains a ubiquitin-binding domain; therefore,
when the ubiquitin-proteasome system is impaired,
this HDAC has an important role in autophagy-
dependent protein degradation44. Furthermore,
HDAC6 overexpression increases autophagosome
formation in various liver cancer cells by activating
c‐Jun NH2‐terminal kinase (JNK)45. Additionally,
HDAC6 depletion impairs serum starvation-induced
autophagy. In serum-starved cervical carcinoma
cells, increased LC3 acetylation resulting from
HDAC6 inhibition correlated with decreased
autophagic flux46. HDAC6 is also important for
autophagosome-lysosome fusion. HDAC6 knockout
impaired the fusion of autophagosomes and
lysosomes by perturbing the formation of F-actin
networks mediated by acetylation of cortactin47.
Another class IIb deacetylase, HDAC10, promotes
autophagy in neuroblastoma cells, and its
knockdown disrupts autophagic flux48. In most
studies, depletion of class I and IIa HDACs is
associated with the enhanced expression of
autophagy regulators involved in the induction
steps, which results in the upregulation of
autophagy. By contrast, inhibition of class IIb
HDACs, such as HDAC6 and HDAC10, is more
associated with the blockade of autophagic flux.
2. Sirtuins
The sirtuin family of class III HDACs are NAD
+ -dependent deacetylases that modulate a variety of
cellular processes, including energy metabolism, stress
responses, cell survival and proliferation. The
deacetylation reactions catalyzed by sirtuins are
coupled to the cleavage of NAD+ into nicotinamide
and 1-O-acetyl-ADP ribose. Therefore, sirtuin
activities are dependent on the availability of cellular
NAD+ and are influenced by cellular metabolic
status. Seven sirtuins (SIRT1 to SIRT7) have been
identified in the human genome, and recent studies
have proposed important roles for all sirtuins in the
regulation of autophagy49–56. In particular, SIRT1
deacetylates ATG5, ATG7 and LC3 and appears to
positively regulate autophagy at several steps49.
KATs and KDACs in neurodegenerative disease
Most of the neurodegenerative diseases in humans are
caused by toxic intracytoplasmic, aggregate-prone pro-
teins. Alzheimer’s disease (AD) pathology is characterized
by amyloid-beta, an extracellular product derived from
amyloid precursor protein (APP), and intracellular
aggregated tau57. Parkinson’s disease (PD) is associated
Fig. 3 Regulation of autophagy by p300-dependent acetylation.
Ac-CoA activates p300, which acetylates Raptor, leading to mTORC1
activation, which inhibits autophagy. Under nutrient (e.g., leucine)
deprivation conditions, autophagy activation is mainly mediated by
decreased Raptor acetylation to inhibit mTORC1.
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with the accumulation of alpha-synuclein (α-syn), and
excess levels of this protein are sufficient to cause dis-
ease58. Huntington’s disease is a monogenic autosomal
dominant disease caused by polyglutamine tract expan-
sions in the huntingtin protein, while amyotrophic lateral
sclerosis (ALS) can be either monogenic or complex. The
monogenic causes of ALS include mutations in SOD1,
FUS and TDP-4359. Importantly, all of these disease-
causing intracytoplasmic proteins are autophagy sub-
strates, and autophagy-upregulating drugs and genes
enhance the clearance of these proteins and attenuate
their toxicities in a range of animal models (flies, zebrafish
and mice)60–69. Autophagy may also protect against
neurodegeneration by dampening inflammatory-type
processes and apoptosis70,71.
The importance of acetylation regulated by KATs and
KDACs in neurodegenerative diseases has been high-
lighted by observations that imbalanced acetylation causes
progressive neuron-specific loss, impaired neuronal
function, and eventual neuronal death72. Many studies
have reported that abnormal acetylation and deacetylation
are linked to the pathogenesis of a variety of neurode-
generative diseases73 (Table 2). We briefly review the
relationships between acetylation and different neurode-
generative diseases to reveal some of the complexities that
may emerge when perturbing relevant modifying
enzymes, as these may impact not only autophagy but also
numerous other cellular processes pertinent to
neurodegeneration.
1. Alzheimer’s disease (AD)p300-mediated histone H3
acetylation at the presenilin 1 (PS1) and beta-site
amyloid precursor protein-cleaving enzyme 1
(BACE1) promoters is upregulated, consequently
enhancing the expression levels of these genes in an
AD model cell line74. Interestingly, p300 levels are
significantly increased in an AD model cell line,
suggesting that p300 regulates the expression of AD-
related genes by controlling acetylation or their
promoters. The overexpression of CBP leads to
recovered loss of learning and memory in AD triple
transgenic mice75. On the other hand, acetylation of
tau can be modulated by p300 and SIRT1, and
excess acetylated tau may contribute to tau-
mediated neurodegeneration76. Interestingly,
hyperactivation of p300/CBP activity has been
reported to disrupt autophagic flux and cause
excessive tau secretion77. PCAF knockout mice are
resistant to Aβ-induced toxicity and memory
deficits, an effect that has been attributed to the
upregulation of the activity of the Aβ-degrading
enzyme Neprilysin78. Impaired function of TIP60
has been described in the human AD hippocampus,
and imbalanced TIP60/HDAC2 activity is observed
in the brain of an APP Drosophila AD model,
suppressing the activities of neuroplasticity genes,
which can be rescued by overexpression of TIP6079.
Inactivation of HDAC1 activity by the p25/Cdk5
complex, which is involved in neurodegenerative
diseases, including AD, causes double-strand DNA
breaks and neurotoxicity, which can be restored by
HDAC1 overexpression80. Moreover, HDAC3
promotes tauopathy, whereas suppression of
HDAC3 may affect not only nonamyloidogenic
APP processing but also neuroprotective gene
expression in vitro and in an AD mouse model81.
Nuclear translocation of class II HDACs such as
HDAC4 and HDAC6 is regulated by Aβ oligomers
and the apolipoprotein E ε4 allele (apoE4), which is a
critical AD risk factor, resulting in the
downregulation of BDNF expression, which is
important for controlling synaptic repair and
synaptic plasticity82. HDAC6 binds to tau in the
perinuclear aggresomal compartment, and HDAC6
levels are upregulated in the hippocampus of AD
patients and AD mice83. By contrast, loss of HDAC6
improves learning and memory, α-tubulin
acetylation and cognitive function in an AD mouse
model84. In the brains of an AD mouse model,
overexpression of SIRT1 inhibits Aβ oligomers and
plaque burden and ameliorates behavioral deficits,
suggesting a neuroprotective role for SIRT1 in AD85.
Loss of SIRT2 induces microtubule stabilization and
initiation of the subsequent autophagic-lysosomal
pathway to degrade toxic Aβ oligomers in an AD-
derived cell model85.
2. Parkinson’s disease (PD)While α-syn is believed to
be an important effector of PD because of its
activities in the cytoplasm, α-syn may also mediate
neurotoxicity by interacting with histone H3,
thereby inhibiting histone acetylation by
inactivating several KATs, including CBP, p300
and PCAF86. The suppression of SIRT2 by either
siRNA or a potent inhibitor prevents α-syn-
dependent neurotoxicity, as well as the formation
of α-syn inclusions in vitro and in a Drosophila
model of PD87. However, the relationship between
SIRT2 inhibition and α-syn aggregation is still
unclear. In cortical Lewy bodies, α-syn colocalizes
with the microtubule-binding proteins MABP1 and
tau. Increased acetylation of α-tubulin by the
inhibition of SIRT2 may promote the formation of
α-syn aggregates by binding to microtubules,
suggesting that stabilized microtubules can play an
important role in neuroprotection87. Furthermore,
the upregulation of SIRT2 prevents microtubule
hyperacetylation and axonal degeneration88. The
overexpression of SIRT1 increases the lifespan of an
α-syn A53T PD mouse model and prevents the
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formation of α-syn aggregates. SIRT1 deacetylates
HSF1 (heat shock factor 1) and thereby increases
Hsp70 levels, suggesting that Hsp70 activation can
inhibit the α-syn-mediated neurotoxicity of Hsp7089.
3. Huntington’s disease (HD)CBP is observed in the
aggregates formed by mutant huntingtin (mHtt)90.
PolyQ expansions, the mutations in the huntingtin
protein, directly interact with and sequester CBP
and PCAF in animal models, leading to
transcriptional dysregulation91. In addition, loss of
CBP from the nucleus impairs HAT activity and
CBP-mediated gene expression, resulting in
neuronal dysfunction and neuronal death92,93.
Furthermore, soluble mHtt may enhance
ubiquitination to accelerate CBP degradation via
the ubiquitin-proteasome system94. mHtt
acetylation at lysine 444 (K444) by CBP activation
or HDAC1 inhibition promotes its trafficking to
autophagosomes and subsequent clearance in
primary neurons and a C. elegans HD model,
suggesting a role in neuroprotection95. Similarly,
HDAC6-mediated retrograde transport on
microtubules may facilitate mHtt degradation
through autophagy44. Several studies have reported
that SIRT1 activity ameliorates mHtt-mediated
toxicity in both cellular and animal models. In
addition, mHtt suppresses SIRT1 deacetylase activity
through a direct interaction causing SIRT1 to
remain hyperacetylated, leading to the attenuation
of SIRT1-regulated neuroprotective effects96.
However, SIRT2 controls HD-related metabolism,
such as cholesterol biosynthesis, leading to increased
production of cholesterol, further increasing mHtt
aggregation97.
4. Amyotrophic lateral sclerosis (ALS)
Transgenic mice expressing the disease-causing
mutant protein SOD1 G86D have low levels of
histone H3 acetylation and CBP in motor neurons98.
Similar to SOD ALS mouse models, low levels of
CBP are found in the motor neurons of sporadic
ALS patients99. Furthermore, SOD1 mutants may
cause disrupted axonal transport and contribute to
the loss of mitochondria from axons because of
defective microtubule-dependent trafficking100.
Interestingly, decreased acetylation of α-tubulin is
observed in HAT Elp3-deficient cortical neurons101.
Knocking out HDAC6 in SOD1 G93A-expressing
mice reduces motor neuron degeneration and
increases acetylated α-tubulin without affecting
disease onset102. However, conflicting functions of
HDAC6 in mice harboring mutant SOD1 have also
been reported. Inhibition of HDAC6 promotes the
formation of large mutant SOD1 aggregates, which
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tubulin and enhanced microtubule retrograde
transport. Interestingly, HDAC6 specifically binds
to mutant SOD1 through SOD1 mutant interaction
region (SMIR) motifs103. Other ALS-causing
proteins, namely, TDP-43 and FUS/TLS, appear to
interact with HDAC6 to control mRNA expression
levels. Moreover, the downregulation of TDP-43
lowers the levels of HDAC6, leading to disrupted
aggregate formation104. G93A SOD1 induces DNA
damage and subsequently facilitates apoptosis by
activating p53105. p53 K320 acetylation is modulated
by p300/CBP and PCAF and produces
neuroprotective effects, including neurite
outgrowth and axon regeneration106. Furthermore,
p53 K382 acetylation is controlled by p300/CBP and
SIRT1, thereby facilitating neuronal apoptosis106.
Concluding remarks
Although the mechanisms remain incompletely under-
stood, accumulating evidence indicates that different
KATs and KDACs play pivotal roles in autophagy reg-
ulation at multiple steps of the pathway. New links
between protein acetylation and autophagy control are
likely to emerge. Acetylation also plays a crucial reg-
ulatory role in pathological conditions, particularly in
neurodegenerative diseases and cancer. Thus, identifying
how acetylation impacts various processes involved in
neurodegenerative diseases, including autophagy, will
help to inform suitable therapeutic strategies.
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